- Conditions
- Infertility, Endometriosis
- Interventions
- Elagolix 200 MG, Placebo or SOC IVF
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • New Haven, Connecticut • Chicago, Illinois + 2 more
Northwestern University clinical trials
Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Live official records
Open in full search- Conditions
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
- Interventions
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
- Interventions
- romidepsin, lenalidomide, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 5
- States / cities
- Duarte, California • New Haven, Connecticut • Chicago, Illinois + 2 more
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Bladder Cancer AJCC v8, MTAP Deletion
- Interventions
- Biospecimen Collection, Computed Tomography, Pemetrexed
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Orland Park, Illinois
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Tomivosertib
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Psychopathology, Child Mental Health, Anxiety Disorders, Mental Disorders, Inflamation, Poverty
- Interventions
- Psychological fMRI task
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
- Interventions
- ibrutinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Lake Forest, Illinois • Boston, Massachusetts + 2 more
- Conditions
- Resectable Intrahepatic Cholangiocarcinoma
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Futibatinib, Gemcitabine, Magnetic Resonance Imaging
- Procedure · Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Postpartum
- Interventions
- Participant will view a visual aid picture (appendix A) first, Participant will view a visual aid picture (appendix B) first
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Amputation of Lower Limb
- Interventions
- Prosthetic foot, Physical therapy
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pain, Postoperative
- Interventions
- Morphine Sulfate, Placebo
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Menstruation; Heavy
- Interventions
- Nighttime Feminine Product
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
About this Northwestern University sponsor directory page
- What this page lists
- U.S. ClinicalTrials.gov public records where Northwestern University is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Northwestern University trials.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.
Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, trials at Northwestern Medicine in Chicago, IL, or open the full search for Northwestern University.